Qure shares finished the regular trading week down only 9% despite the FDA’s hard-line stance and public criticism against the company’s Huntington’s disease (HD) gene therapy candidate AMT-130.

Cancer remains a leading cause of global morbidity and mortality, and conventional therapeutic strategies are often limited by poor tumor selectivity, ...